Mabpharm Ltd (2181) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Mabpharm Ltd stock HK$0.13, price HK$0.49, that is 73.5% below the price, quality 55 out of 100. Rating: strongly overvalued. Calculated from audited financials with 13 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Mabpharm Ltd
2181 · HKFar too expensive (fair value 74% below the price) and price moving sideways, but solid company: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range HK$0.2500 – HK$1.31 · fair‑value band HK$0.0700 – HK$0.2300 · the HK$0.4900 price screens above the HK$0.1300 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Mabpharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Mabpharm Limited, a biopharmaceutical company, engages in research, development, production, and commercialization of drugs and biosimilar for cancers and autoimmune diseases in the People's Republic of China.
Show moreShow less
It offers CMAB007, a recombinant humanized anti-immunoglobulin E monoclonal antibody for treatment of asthma patients; CMAB009, a recombinant anti-EGFR chimeric monoclonal antibody for the first-line treatment of metastatic colorectal cancer; and CMAB008, a recombinant anti-TNF-alpha chimeric monoclonal antibody for the treatment of ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, Crohn's disease in adults and pediatric patients aged above 6 years old, fistula Crohn's disease, and psoriasis.
The company also develops CMAB807/CMAB807X that has completed Phase III clinical trial for the treatment of osteoporosis, tumor bone metastasis, and giant-cell tumor of bone; CMAB819 that has completed Phase I clinical trial for the treatment of metastatic non-small cell lung cancer, hepatocellular carcinoma, and head and neck squamous cell carcinomas; and CMAB015, a biosimilar candidate for secukinumab to treat psoriasis and ankylosing spondylitis that is in Phase I clinical trial.
In addition, its products under the pre-clinical stage include CMAB017 for the treatment of advanced solid tumors; CMAB016, a biosimilar product candidate of dupilumab for the treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease (COPD), and prurigo nodularis; CMAB022 for the treatment of inflammatory diseases; and CMAB023, a biosimilar drug candidate for Tezepelumab.
Further, the company is involved in research and development, manufacturing, technical consulting, technology transfer, and technical services of biological products, chemical biological reagents, diagnostic reagents, and drugs.
Mabpharm Limited was incorporated in 2018 and is headquartered in Taizhou, China.
Stock analysis
Mabpharm Ltd (2181) currently trades at HK$0.4900, while our model-based Fair Value estimate is HK$0.1300, 74% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of HK$0.7400 per share, and 4 of the 13 models we run sit above the HK$0.4900 price.
Bear case: the Economic Profit group reads lowest at HK$0.0750, and 9 of the 13 models stay below the price. Data coverage for this calculation is low.
Scenario range: HK$0.0700 (bear) to HK$0.2300 (bull), the price of HK$0.4900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 55/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Mabpharm Ltd reported revenue of 629M CNY in FY2025 versus 82.9M CNY in FY2021, a compound +66.0%/yr. Reported net income was 55.7M CNY in FY2025.
Key figures
Market cap HK$2.0B (≈ $258M) Micro · P/E ratio 21.8 · P/S ratio 1.92 · Net margin 8.8% · Return on equity 58.5% · Return on assets (EBIT) −17.7% (5-year average) · Operating margin 8.5% · Revenue (TTM) 770M CNY.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 56 out of 100 (low confidence).
What moves the price
The share trades about 32% below its 52-week high and 32% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −74%, 2181 screens richer than that median.
Fair Value models
All 13 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare Mabpharm Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Dividend yield by industry
- EV/EBITDA by industry
- PEG screener for stocks with fair value
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $955.47 | $1,275 | +33% | vs 2181 |
| Vertex Pharmaceuticals Incorporated VRTX | $538.60 | $592.46 | +10% | vs 2181 |
| Samsung Biologics Co 207940 | 1,411,000 KRW | 1,552,100 KRW | +10% | vs 2181 |
| Genmab A/S GMAB | kr 3,448 | kr 3,793 | +10% | vs 2181 |
| argenx SE ARGX | $960.04 | $908.40 | −5% | vs 2181 |
| CSL Limited CSL | A$202.52 | A$185.51 | −8% | vs 2181 |
| Moderna, Inc MRNA | $223.37 | $139.99 | −37% | vs 2181 |
| Revolution Medicines, Inc RVMD | $172.29 | $88.78 | −48% | vs 2181 |
| Celltrion, Inc 068270 | 214,000 KRW | 74,945 KRW | −65% | vs 2181 |
| Royalty Pharma plc RPRX | $69.31 | $19.01 | −73% | vs 2181 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Mabpharm Ltd (2181) overvalued or undervalued?
What is the fair value of 2181?
What is the quality score of 2181?
What is the price target for Mabpharm Ltd (2181)?
What is the Mabpharm Ltd stock forecast for 2026?
What is the revenue of Mabpharm Ltd (2181)?
What is the intrinsic value of Mabpharm Ltd (2181)?
Is Mabpharm Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2181?
How much is Mabpharm Ltd worth?
What do the bullish and bearish scenarios say about 2181?
What is the P/E ratio of 2181?
How solid is the balance sheet of Mabpharm Ltd (2181)?
How far is 2181 from its 52-week high?
Which stocks are comparable to Mabpharm Ltd?
Is Mabpharm Ltd stock attractive at the current price?
How is the fair value of 2181 calculated?
Is it still worth investing in stocks now?
What is the share price of Mabpharm Ltd (2181)?
What should I pay attention to with Mabpharm Ltd right now?
Key figures of Mabpharm Ltd
How large is the market capitalisation of Mabpharm Ltd (2181)?
What is the P/S ratio of Mabpharm Ltd (2181)?
What is the net margin of Mabpharm Ltd (2181)?
What is the return on equity of Mabpharm Ltd (2181)?
What is the EBIT return on assets of Mabpharm Ltd (2181)?
What is the operating margin of Mabpharm Ltd (2181)?
How fast is revenue growing at Mabpharm Ltd (2181)?
How fast are earnings growing at Mabpharm Ltd (2181)?
How much free cash flow does Mabpharm Ltd (2181) generate?
How much net debt does Mabpharm Ltd (2181) carry?
Watch Mabpharm Ltd in the live analysis
One click puts Mabpharm Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.